| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
Sector: Pharmaceuticals
| Eli Lilly's recent product and service development efforts are characterized by a robust pipeline, particularly in obesity and diabetes treatments, enhancing the company's market position. The successful approval of innovative drugs and targeted treatments in advanced cancer signifies a commitment to addressing significant health challenges. Strong clinical progress and the launch of new products further contribute to positive growth prospects. However, ongoing innovation and market competitiveness will necessitate sustained focus to maintain momentum. |
| The price action of Eli Lilly (LLY) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at -0.1 is modestly bearish. The market sentiment at 1.4 is very bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next. There is no clear direction for LLY since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 1.5, and the negative at -0.1 on 2026-09-21. The forces of Sector Price Trend (-0.5), and Stock Price Trend (-0.1) will drive down the price. The forces of Price Level Sentiment (0), Valuation Sentiment (0.7), Option Sentiment (0.8), Market Risk Appetite (3), and Sentiment towards Fundamentals (4.2) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice notifications on Market Movers
| LLY | ||||||||||||||||
| Date | Attention | Price | StdDev | Price Level | RSI | Hourly RSI | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-21 | 0%(0.1%) | 1164.66 | 2.85% | 54 | 54 | 63 | 1.03% | 0.14% | -0.1 | 0.2 | 0.7% | 1.4 | Long | 55% | 4.2 | 6.3 |
| 2026-09-20 | 0%(0.1%) | -0.2 | 0.2 | 0.7 | 3.8 | -1 | ||||||||||
| 2026-09-19 | 0%(0.1%) | -0.2 | 0.2 | 0.7 | 3.8 | -1 | ||||||||||
| 2026-09-18 | 0%(0.1%) | 1152.73 | 3.41% | 43 | 40 | 58 | 0.04% | -0.06% | -0.2 | 0.2 | 0.4% | 1.3 | Long | 55% | 4.2 | 6.3 |
| 2026-09-17 | 0%(0.1%) | 1152.25 | 3.74% | 41 | 39 | 62 | 1.18% | -0.07% | -0.5 | 0.3 | 0.4% | 0.6 | Wait | 50% | 3.8 | -1 |
| 2026-09-16 | 0%(0.1%) | 1138.8 | 4.34% | 32 | 26 | 44 | 0.16% | -0.18% | -0.5 | -0.1 | 0.4% | 0.5 | Short | 55% | 3.9 | -1 |
| 2026-09-15 | 1%(0.1%) | 1136.98 | 4.39% | 29 | 17 | 47 | -0.01% | -0.18% | -0.3 | -0.2 | 0.9% | 0.2 | Short | 55% | 3.3 | 6.8 |
| 2026-09-14 | 0%(0%) | 1137.15 | 4.31% | 28 | 16 | 64 | 1.97% | -0.32% | -0.6 | 0.1 | 1% | 0.2 | Wait | 50% | 1.7 | -1 |
| 2026-09-13 | 0%(0%) | -1.3 | 0.1 | -0.2 | 2 | -1 | ||||||||||
| 2026-09-12 | 0%(0%) | -1.3 | 0.1 | -0.2 | 1.9 | -1 | ||||||||||
| Long is the preferred trading strategy with 55% chance of being right. Improving trend sentiment and positive hourly trend. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||||
| Analysis | ||
| ● Eli Lilly (LLY) – Equity Research Report Tue. Mar 17, 2026 | ||
| 2026-09-21 23:15:43 The CEO's comments provide a strong signal of leadership confidence which is seen as a positive driver for investor sentiment. |
| 2026-09-21 23:15:43 The article highlights encouraging updates from Eli Lilly's CEO that strengthen the positive expectations regarding the stock's performance. |
| 2026-09-21 17:01:18 Analysts provide insights and forecasts regarding Eli Lilly's market performance and expected future developments. |
| 2026-09-21 17:01:18 There are discussions regarding the market's potential mispricing of Eli Lilly's stock in light of its strong revenue growth. |
| 2026-09-21 17:01:18 The articles highlight competition in the pharmaceutical market, particularly related to weight-loss treatments and how it's impacting stock movements. |
| 2026-09-21 17:01:18 Eli Lilly is experiencing significant revenue growth, which contrasts with its stock performance, indicating strong earnings potential. |
| 2026-09-21 17:01:18 The articles discuss the current performance of Eli Lilly's stock, noting fluctuations and comparisons to previous years. |
| 2026-09-21 15:47:22 The increase in the number of seniors using Lilly's GLP-1 drugs is likely to positively impact the company's earnings in the pharmaceutical industry. |
| 2026-09-21 15:47:22 The implementation of Medicare coverage has led to a significant number of seniors utilizing GLP-1 medications, reflecting positively on regulatory changes. |
| 2026-09-21 15:47:22 The expansion of Medicare coverage for GLP-1 medications is significantly increasing access for seniors, highlighting a positive trend in medication accessibility. |
| 2026-09-21 13:47:24 CEO Dave Ricks expresses confidence in the long-term prospects of Eli Lilly's presence in the pill segment, reflecting a strong leadership vision. |
| 2026-09-21 13:47:24 Eli Lilly's investment in a new $6.5 billion manufacturing facility indicates a commitment to enhancing production capacity and meeting market demands. |
| 2026-09-21 13:47:24 The competition with Novo and the need for Eli Lilly to ramp up production highlights the ongoing rivalry in the diabetes medication sector. |
| 2026-09-21 13:47:24 The recent launch of Eli Lilly's GLP-1 pill, Foundayo, signifies the company's efforts to establish its presence in the competitive diabetes treatment market. |